CN117659204A - Tetrameric antibody complex and application thereof - Google Patents
Tetrameric antibody complex and application thereof Download PDFInfo
- Publication number
- CN117659204A CN117659204A CN202410134120.4A CN202410134120A CN117659204A CN 117659204 A CN117659204 A CN 117659204A CN 202410134120 A CN202410134120 A CN 202410134120A CN 117659204 A CN117659204 A CN 117659204A
- Authority
- CN
- China
- Prior art keywords
- antibody
- tetrameric
- region
- bispecific
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011324 bead Substances 0.000 claims abstract description 46
- 210000004027 cell Anatomy 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 27
- 229920002307 Dextran Polymers 0.000 claims description 18
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 17
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 15
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 15
- 241000283707 Capra Species 0.000 claims description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 10
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 9
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 9
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 9
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 9
- 239000007790 solid phase Substances 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 238000012412 chemical coupling Methods 0.000 claims description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 3
- 241000283086 Equidae Species 0.000 claims description 2
- 241000283074 Equus asinus Species 0.000 claims description 2
- 229920001503 Glucan Polymers 0.000 claims description 2
- 241000282887 Suidae Species 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 229920003192 poly(bis maleimide) Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000912781 Carcharhinus galapagensis Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 1
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 1
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 1
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 1
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to the technical field of biological diagnosis, in particular to a tetrameric antibody complex and application thereof. The invention provides a double antibody, so that the Fab section of the double antibody molecule is respectively resistant to two different antibody molecules or different parts of the Fc section of the same kind of antibody, and the aim of cell sorting is achieved by connecting magnetic beads with target cells through a specific tetramer consisting of four antibodies. The specific double-antibody can form a single tetramer product with other two antibodies, effectively avoids the generation of tetramer invalid products, greatly improves the utilization efficiency of the antibodies and reduces the use cost of the antibodies.
Description
Technical Field
The invention relates to the technical field of biological separation and purification, in particular to a tetrameric antibody complex and application thereof.
Background
With the continuous development of cell therapy and gene therapy (CGT) technology, related researches such as transformation of cells and in vitro amplification culture have gradually become research hotspots in the field of life science, and in-depth research on the cells, separation and purification of specific target cells are required to obtain purer target cells, so that cell sorting has become an important link of related researches.
Currently, cell sorting methods based on immunorecognition properties include Fluorescence Activated Cell Sorting (FACS) and Magnetic Activated Cell Sorting (MACS). FACS is a "gold standard" for sorting cells using a flow cytometer, although considered as a "gold standard" for cell sorting, it requires relatively expensive, time-consuming equipment, and requires a high level of technical support and specialized operators; meanwhile, FACS has a larger influence on the activity of the separated cells because of larger stimulation on the cells; on the other hand, FACS sorted cells have low throughput, cell sorting of multiple samples cannot be achieved, and it is often difficult to obtain enough cells at a time, which is only suitable for small-scale research work. Magnetic cell sorting (MACS) cells were purified by magnetic separation by incubating the sample cells with immunomagnetic beads conjugated with antibodies. Compared with FACS, the MACS method is a cell sorting technology combining the high specificity of immunological reaction and the special magnetic responsiveness of magnetic beads, and has the advantages of high efficiency, convenience, no need of special equipment, simple operation and low technical requirements on operators. And the influence on cells can be basically ignored, and the separated cells have higher recovery rate and cell activity, have smaller influence on downstream application, and are superior to flow separation in the aspect of maintaining the cell activity, so that the method has a very large application prospect.
In the existing magnetic activated cell sorting method, the Stem cell company marks magnetic beads by an antibody Tetramer (TAC) mode to realize cell separation, and the defects of the traditional chemical connection coupling mode are overcome, such as: 1. the activity of the antibody is destroyed, and the spatial orientation of the antibody cannot be ensured; 2. the antibody has low coupling efficiency, is easy to lose efficacy and is not easy to store. The TAC in this method consists of two mouse IgG1 antibodies and two rat anti-mouse IgG1 antibodies. Two mouse antibodies were linked by two rat anti-mouse IgG1 antibodies, one of which specifically bound to the desired cells and the other bound to dextran coated on the magnetic beads (as shown in fig. 1). When the desired cells are bound to the magnetic beads, they are left on the column while passing through the column placed on the magnetic pole, and the undesired cells pass through the column. The cells remaining on the column were collected for subsequent investigation. However, the method has the probability of forming ase:Sub>A complex (A-B-C) with ase:Sub>A structure shown in the figure in the process of forming the TAC antibody complex of about 30 percent, and can also form ineffective tetramer complexes of A-B-A and C-B-C, thereby reducing the coupling efficiency and greatly reducing the antibody utilization rate.
Disclosure of Invention
In view of the above, the present invention provides a Tetrameric Antibody Complex (TAC) and its application.
The present invention provides tetrameric antibody complexes comprising four antibodies, wherein antibody a and antibody C are linked by one bispecific antibody B, bispecific antibody B being F (ab') 2 regions from different antibodies, respectively, linked to each other;
two F (ab') 2 regions of the bispecific antibody B, targeting the Fc region of antibody a and the Fc region of antibody C, respectively;
the antibody A targets the target to be detected, the antibody C targets the solid phase carrier, and the Fc region of the antibody A and the Fc region of the antibody C are derived from different species.
Further, the method comprises the steps of,
the target to be detected targeted by the antibody A is a cell surface antigen;
the solid phase carrier targeted by the antibody C is a magnetic bead, a microsphere, a slide or a chip, and dextran and/or dextrin are modified on the surface of the solid phase carrier.
Still further, in the tetrameric antibody complex of the present invention, the cell surface antigen includes, but is not limited to, at least one of CD3, CD4, CD8, CD16, CD19, CD45, CD56, CD 138.
Further, in the tetrameric antibody complex of the present invention, the bispecific antibody B does not contain an Fc region; the Fc region of antibody A and the Fc region of antibody C are independently selected from the Fc regions of sheep, mice, rabbits, horses, pigs, or donkeys.
In some embodiments of the present invention,
the antibody A specifically recognizes at least one of CD3, CD4, CD8, CD16, CD19, CD45, CD56 and CD 138;
the antibody C specifically recognizes dextran;
the bispecific antibody B does not contain an Fc region, and wherein on one side F (ab ') 2 specifically recognizes the Fc region of antibody A and on the other side F (ab') 2 specifically recognizes the Fc region of antibody C;
wherein the bispecific antibody B is formed by coupling F (ab') 2 against the Fc-terminus of two antibodies of different species to each other. In some embodiments, the bispecific antibody B is conjugated by PDM from the Fc-terminal F (ab') 2 of antibodies against two different species. The anti-two different species antibodies are selected from: any two of goat anti-mouse, goat anti-rabbit, goat anti-human, goat anti-monkey, or selected from: any two of a mouse-anti-sheep, a mouse-anti-rabbit, a mouse-anti-human, a mouse-anti-monkey, or any two selected from a rabbit-anti-sheep, a rabbit-anti-human, a rabbit-anti-monkey, and a rabbit-anti-mouse.
In some embodiments of the present invention, in some embodiments,
the antibody A is a mouse anti-human CD3 antibody, a mouse anti-human CD4 antibody or a mouse anti-human CD8 antibody;
the antibody C is a rabbit anti-glucan antibody;
the bispecific antibody B was prepared from goat F (ab ') 2 anti-mouse IgG Fc and goat F (ab') 2 anti-rabbit IgG Fc.
The invention provides a novel tetrameric antibody complex, which comprises a molecule of bispecific antibody and an antibody A and an antibody C which are specifically combined with the bispecific antibody, wherein the combination mode successfully avoids the problem of high invalid products of the tetrameric antibody complex in the prior art, greatly improves the purity and the yield of the tetrameric antibody complex and reduces the cost of synthesizing the tetrameric antibody complex.
The invention provides a preparation method of the tetrameric antibody complex, which comprises the steps of obtaining a bispecific antibody B by a chemical coupling method, mixing the bispecific antibody B with an antibody A and an antibody C, and incubating the mixture to prepare the tetrameric antibody complex
Further, in the preparation method of the invention,
the molar ratio of the bispecific antibody B, antibody a and antibody C is 1:1:1, a step of;
the mixing time is 5-30 min.
The present invention provides conjugates comprising a tetrameric antibody complex of the present invention and a solid support.
Furthermore, the solid phase carrier is dextran modified magnetic beads, and the diameter of the dextran modified magnetic beads is 50 nm-5 mu m.
The invention provides the tetrameric antibody complex, the tetrameric antibody complex prepared by the preparation method or the application of the conjugate in cell separation and purification.
The invention also provides a reagent for separating and purifying cells, which comprises the tetrameric antibody complex, the tetrameric antibody complex prepared by the preparation method or the conjugate in the cells.
Also included in the reagents are buffers including, but not limited to, PBS buffer, HEPES buffer, TBE buffer, tris buffer, TAE buffer, or carbonate buffer.
The invention provides a method for separating and purifying cells, which comprises the step of separating target cells in a sample by using the tetrameric antibody complex, the tetrameric antibody complex prepared by the preparation method or the conjugate.
Further, the sample includes a tissue sample, whole blood, PBMCs, and the like.
The invention provides a double antibody, so that the Fab section of the double antibody molecule is respectively resistant to two different antibody molecules or different parts of the Fc section of the same kind of antibody, and the aim of cell sorting is achieved by connecting magnetic beads with target cells through a specific tetramer consisting of four antibodies. The bispecific anti-antibody can form a single tetramer product with other two antibodies, effectively avoids the generation of tetramer invalid products, greatly improves the utilization efficiency of the antibodies and reduces the use cost of the antibodies.
Drawings
FIG. 1 is a schematic representation of a prior art antibody tetramer complex;
FIG. 2 is an improved antibody tetramer complex of the present invention;
FIG. 3 is a diagram showing three forms of a specific bispecific antibody, namely, a bispecific antibody formed by connecting variable regions of two antibodies from left to right, a bispecific antibody formed by connecting a variable region of an antibody A (comprising a variable region, a CH1 segment and a constant region) with a variable region of an antibody B, and a bispecific antibody formed by connecting an antibody A (comprising a variable region and a constant region) with a variable region of an antibody B;
FIG. 4 is a schematic diagram of a universal dual antibody chemical coupling;
FIG. 5 is a comparison of CD3 positive cell changes in supernatants before and after positive sorting of human CD3 cells;
FIG. 6 is a comparison of CD4 positive cell changes in supernatants before and after positive sorting of human CD4 cells;
FIG. 7 is a comparison of CD8 positive cell changes in supernatants before and after positive sorting of human CD8 cells.
Detailed Description
The present invention provides Tetrameric Antibody Complexes (TAC) and uses thereof, and those skilled in the art can, given the teachings herein, suitably modify the process parameters to achieve. It is expressly noted that all such similar substitutions and modifications will be apparent to those skilled in the art, and are deemed to be included in the present invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the relevant art that the invention can be practiced and practiced with modification and alteration and combination of the methods and applications herein without departing from the spirit and scope of the invention.
Unless defined otherwise herein, scientific and technical terms used in connection with the present invention shall have the meaning as understood by one of ordinary skill in the art.
The terms "comprising," "including," and "having" are used interchangeably herein to mean that the elements are included in an arrangement, meaning that the arrangement may exist in addition to the elements listed. It should also be understood that the use of "including," "comprising," and "having" descriptions herein also provides a "consisting of … …" scheme.
The term "and/or" as used herein includes the meaning of "and", "or" and "all or any other combination of the elements linked by the term of interest".
In the present application, "at least one" means one or more, and "a plurality" means two or more. "at least one of" or the like means any combination of these items, including any combination of single item(s) or plural items(s).
The term "antibody" is used herein in its broadest sense to refer to a polypeptide or combination of polypeptides that comprises sufficient sequence from an immunoglobulin heavy chain variable region and/or sufficient sequence from an immunoglobulin light chain variable region to be able to specifically bind to an antigen. The term "antibody" as used herein encompasses various forms and structures, provided that they exhibit the desired antigen binding activity.
The term "antibody" herein includes a typical "four-chain antibody" which belongs to an immunoglobulin consisting of two Heavy Chains (HC) and two Light Chains (LC); heavy chain refers to a polypeptide chain consisting of a heavy chain variable region (VH), a heavy chain constant region CH1 domain, a Hinge Region (HR), a heavy chain constant region CH2 domain, a heavy chain constant region CH3 domain in the N-to C-terminal direction; and, when the full length antibody is an IgE isotype, optionally further comprising a heavy chain constant region CH4 domain; the light chain is a polypeptide chain consisting of a light chain variable region (VL) and a light chain constant region (CL) in the N-terminal to C-terminal direction; the heavy chains and the light chains are connected through disulfide bonds to form a Y-shaped structure. The antigenicity of the immunoglobulin heavy chain constant region varies due to the different amino acid composition and sequence of the immunoglobulin heavy chain constant region. Accordingly, the "immunoglobulins" herein may be divided into five classes, or isotypes of immunoglobulins, i.e., igM, igD, igG, igA and IgE, the respective heavy chains of which are the μ, δ, γ, α and epsilon chains, respectively. The same class of Ig can be divided into subclasses according to the differences in the amino acid composition of its hinge region and the number and position of the disulfide bonds of the heavy chain, e.g., igG can be divided into IgG1, igG2, igG3, igG4, igA can be divided into IgA1 and IgA2. Light chains are classified by the difference in constant regions as either kappa chains or lambda chains. Each class Ig of the five classes of Igs may have either a kappa chain or a lambda chain.
The term "Fc region" is used herein to define the C-terminal region of an antibody heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. Typically, the IgG Fc region comprises IgG CH2 and IgG CH3 domains, optionally in addition to which a complete or partial hinge region may be included, but no CH1 domain is included. The "CH2 domain" of a human IgG Fc region typically extends from an amino acid residue at about position 231 to an amino acid residue at about position 340.
The "IgG antibody" hydrolyzes IgG with papain, and cleaves the interchain disulfide bond of the heavy chain of IgG near the N-terminus to give three hydrolyzed fragments, two identical Fab fragments and one Fc fragment. The Fab fragment, the antigen binding fragment (fragment of antigenbinding), contains about 1/2 of the N-terminal portion of one complete light and heavy chain, and retains the binding function to the epitope. The Fc segment can crystallize fragment (ragment crystalizable), and contains half of the C-terminal of two heavy chains and disulfide bonds between the heavy chains, so that the original antigenicity of the heavy chains and the biological activity of the original functional region of the heavy chains are maintained. If IgG is hydrolyzed with pepsin, the heavy chain interchain disulfide bond can be cleaved near the C-terminus to yield a F (ab) fragment and a plurality of small molecule polynnaeus fragments (pFC). F (ab ') 2 has the property of binding to two epitopes, whereas pFC' has no biological activity.
The "antibody" herein may be derived from any animal, including but not limited to humans and non-human animals, which may be selected from primates, mammals, rodents and vertebrates, such as camelids, llamas, primo-ostris, alpacas, sheep, rabbits, mice, rats or chondrilleids (e.g. shark).
It should be understood that, in various embodiments of the present application, the sequence number of each process does not mean that the sequence of execution is sequential, and some or all of the steps may be executed in parallel or sequentially, where the execution sequence of each process should be determined by its functions and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.
The numerical ranges and parameters set forth in the present invention are presented as precisely as possible in the specific examples. However, any numerical value inherently contains certain standard deviations found in their respective testing measurements. Thus, unless expressly stated otherwise, it is to be understood that all numerical ranges or specific data used in this disclosure may be reasonably biased within certain ranges, such as: within + -10%, + -5%, + -1% or + -0.5%.
Examples of the present invention and comparative examples are described in some cases. Wherein the embodiments illustrate certain implementations of the invention. However, this does not mean that the effect of the present invention can be achieved only in these cases. In fact, the antibody A targets other targets to be detected, or the antibody C corresponding to other substances modified on the solid-phase carrier targets the modifier on the solid-phase carrier, or other bispecific antibodies B are adopted for coupling, so that similar effects can be realized. The three cases shown in the examples are the three cases with the best effect, but experiments in the research and development process show that the effect of cell capture is not affected by the kind of target to be detected. In addition to the above, some cases of poor effect in the comparative experiments are listed, and many attempts have been made in the development process, for example, different bispecific antibodies B are used, and different materials are modified on the surface of the solid matrix, but the effects of these attempts are not better than those of examples 1 to 3, and are not repeated here.
The reagent consumable adopted by the invention is a common commercial product and can be purchased in the market. The invention is further illustrated by the following examples:
EXAMPLE 1 preparation of bispecific antibodies of the invention
The invention provides a double antibody, which leads the F (ab ') 2 section of the double antibody molecule to be respectively resistant to two different antibody molecules or to different parts of the Fc section of an antibody of the same genus, as shown in figure 2, the F (ab ') 2 at one end of the double-specificity antibody molecule B is resistant to the Fc end of mouse IgG (antibody A), the F (ab ') 2 at the other end is resistant to the Fc end of rabbit IgG (antibody C), the mouse IgG is an antibody of a certain antigen of human cells, and the rabbit IgG is an antibody of anti-dextran magnetic beads, thereby realizing that the magnetic beads are connected with target cells by a specific tetramer consisting of four antibodies, and achieving the purpose of cell sorting. The bispecific antibody can form a single tetramer product with other two antibodies, effectively avoids the generation of tetramer invalid products, greatly improves the utilization efficiency of the antibodies and reduces the use cost of the antibodies.
In addition, by the above method, a specific bispecific antibody can be further prepared directly, for example, a mouse (or other species) anti-human CD3 antibody (antibody a) and a mouse (or other species) anti-dextran antibody (antibody B) can be directly prepared into a bispecific antibody by chemical coupling, hybridoma fusion or gene recombination, and the same cell separation effect can be achieved, as shown in fig. 3.
The preparation process of the bispecific antibody of the present invention comprises the following steps:
two intact IgG or two F (ab) 2 antibody fragments are coupled to one BsAb (as in fig. 4) by chemical coupling agents such as 5,5 '-dithio-bis 2-nitrobenzoic acid (DNTB), phthalimide, N-succinyl-3- (2-pyridyldithio) propionate, dithioacylbenzoic acid, and the like, bifunctional N, N' -o-styrene-bismaleimide (PDM).
The specific process is as follows: the Abcam antibodies were purchased separately: goat F (ab ') 2 anti-mouse IgG-Fc, pre-adsorbed secondary antibody (ab 5872) and goat F (ab ') 2 anti-rabbit IgG Fc (ab 6016) (the procured antibody has been pepsin digested and the Fc portion removed to form a F (ab ') 2 fragment). F (ab ') 2 of one antibody was first linked to bifunctional N, N ' -o-styrene-bismaleimide (PDM), and then the Fab ' fragment of the other antibody was added to form a stable Fab '. Times.Fab ' bispecific antibody (see FIG. 4).
The parameters in the preparation are adjusted according to the antibody yield, and the optimized scheme is as follows: preparing goat anti-mouse F (ab ') 2 fragment into 0.5mg/ml antibody solution, adding PDM with final concentration of 0.5mmol/L into 200 μl of the prepared antibody solution, reacting at 37deg.C for 30min, subjecting to Sephadex G-25 gel column chromatography, monitoring at 225nm, and collecting F (ab ') 2-PDM fragment obtained by reaction of goat anti-mouse F (ab ') 2 fragment and PDM. Goat anti-rabbit F (ab ') 2 fragment was formulated as 0.5mg/ml antibody solution and was conjugated to anti-mouse F (ab') 2-PDM fragment 1:1, reacting for 4 hours at 37 ℃, carrying out Sephadex G-150 gel column chromatography on the reactant, monitoring at 280nm, and collecting heterozygous F (ab') 2 fragments to obtain the bispecific antibody.
2-7 mu l (0.5 mg/ml) of a mouse anti-human CD3 antibody, 2-7 mu l (0.5 mg/ml) of a rabbit anti-dextran IgG type antibody and 4-14 mu l (0.5 mg/ml) of a bispecific antibody are blended for 5-30 min, and 0.3-1 mg (3 mu m magnetic beads about 1.2X10) of 3 mu m dextran magnetic beads (50 nm-5 mu m magnetic beads) are added 9 And (3) continuously combining the magnetic beads/mg for 5-30 min, magnetically sucking to remove the supernatant, washing with PBS for 2-5 times, and finally adding PBS solution to ensure that the concentration of the magnetic beads is 1mg/ml.
As a control, 2 to 7. Mu.l (0.5 mg/ml) of a mouse anti-human CD3 antibody, 2 to 7. Mu.l (0.5 mg/ml) of a mouse anti-dextran IgG type antibody and 4 to 14. Mu.l (0.5 mg/ml) of a goat F (ab') 2 anti-mouse IgG-Fc were blended for 5 to 30 minutes, and 0.3 to 1mg (3. Mu.m magnetic beads about 1.2X10) of 3 μm dextran magnetic beads (50 nm to 5. Mu.m magnetic beads) were added 9 And (3) continuously combining the magnetic beads/mg for 5-30 min, magnetically sucking to remove the supernatant, washing with PBS for 2-5 times, and finally adding PBS solution to ensure that the concentration of the magnetic beads is 1mg/ml.
Calculating the amount of the magnetic beads according to the cell amount required to be separated by the cells, so that the ratio of the magnetic beads to the cells is 1-12: 1, the cell concentration was adjusted to 1X 10 7 Taking the cell/ml, respectively taking the magnetic bead dosage required by calculation of the experimental group and the control group, magnetically sucking to remove the supernatant, adding the cell suspension, and incubating the cells and the magnetic beads for 5-30 miAnd n, collecting cell supernatants after magnetic attraction, and carrying out flow identification, wherein the result is shown in FIG. 5. The initial CD3 cell proportion in PBMC is 59.06%, the CD3 cell proportion is reduced to 47.38% after the control group cells are grabbed, and the CD3 positive cell grabbing rate is about 43.94%; after the specific double antibody experimental group is adopted to grab cells, the grabbing rate of CD3 positive cells is more than 99 percent, and the grabbing rate of cells is obviously improved.
Example 2
The bispecific antibody is prepared by the same method, 2 to 7 mu l (0.5 mg/ml) of a mouse anti-human CD4 antibody, 2 to 7 mu l (0.5 mg/ml) of a rabbit anti-dextran IgG type antibody and 4 to 14 mu l (0.5 mg/ml) of a bispecific antibody are mixed for 5 to 30 minutes, and 0.3 to 1mg (3 mu m magnetic beads about 1.2X10) of 3 mu m dextran magnetic beads (50 nm to 5 mu m magnetic beads) are added 9 And (3) continuously combining the magnetic beads/mg for 5-30 min, magnetically sucking to remove the supernatant, washing with PBS for 2-5 times, and finally adding PBS solution to ensure that the concentration of the magnetic beads is 1mg/ml.
Calculating the amount of the magnetic beads according to the cell amount required to be separated by the cells, so that the ratio of the magnetic beads to the cells is 1-12: 1, the cell concentration was adjusted to 1X 10 7 Taking the amount of magnetic beads required by calculation, magnetically sucking to remove the supernatant, adding cell suspension, incubating cells and the magnetic beads for 5-30 min, magnetically sucking to collect cell supernatant, and performing flow identification, wherein the result is shown in FIG. 6, and the capture rate of CD4 positive cells is over 96.7%.
Example 3
The bispecific antibody is prepared by the same method, 2 to 7 mu l (0.5 mg/ml) of a mouse anti-human CD8 antibody, 2 to 7 mu l (0.5 mg/ml) of a rabbit anti-dextran IgG type antibody and 4 to 14 mu l (0.5 mg/ml) of a bispecific antibody are mixed for 5 to 30 minutes, and 0.3 to 1mg (3 mu m magnetic beads about 1.2X10) of 3 mu m dextran magnetic beads (50 nm to 5 mu m magnetic beads) are added 9 And (3) continuously combining the magnetic beads/mg for 5-30 min, magnetically sucking to remove the supernatant, washing with PBS for 2-5 times, and finally adding PBS solution to ensure that the concentration of the magnetic beads is 1mg/ml.
Calculating the amount of the magnetic beads according to the cell amount required to be separated by the cells, so that the ratio of the magnetic beads to the cells is 1-12: 1, the cell concentration was adjusted to 1X 10 7 Taking the amount of magnetic beads required by calculation, magnetically removing the supernatant, adding cell suspension to obtain cellsIncubating with the magnetic beads for 5-30 min, collecting cell supernatant after magnetic attraction, and carrying out flow identification, wherein the result is shown in fig. 7.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (16)
1. A tetrameric antibody complex comprising four antibodies, wherein antibody a and antibody C are linked to each other by a bispecific antibody B;
two F (ab') 2 regions of the bispecific antibody B, targeting the Fc region of antibody a and the Fc region of antibody C, respectively;
the antibody A targets the target to be detected, the antibody C targets the solid phase carrier, and the Fc region of the antibody A and the Fc region of the antibody C are derived from different species.
2. The tetrameric antibody complex of claim 1,
the target to be detected targeted by the antibody A is a cell surface antigen;
the solid phase carrier targeted by the antibody C is a magnetic bead, a microsphere, a slide or a chip, and dextran and/or dextrin are modified on the surface of the solid phase carrier.
3. The tetrameric antibody complex of claim 2, wherein the cell surface antigen comprises at least one of CD3, CD4, CD8, CD16, CD19, CD45, CD56, CD 138.
4. The tetrameric antibody complex of claim 1, wherein the bispecific antibody B does not contain an Fc region; the Fc region of antibody A and the Fc region of antibody C are independently selected from the Fc regions of sheep, mice, rabbits, horses, pigs, or donkeys.
5. The tetrameric antibody complex according to claim 1 to 4, wherein,
the antibody A specifically recognizes at least one of CD3, CD4, CD8, CD16, CD19, CD45, CD56 and CD 138;
the antibody C specifically recognizes dextran and/or dextrin;
the bispecific antibody B does not contain an Fc region, and wherein on one side F (ab ') 2 specifically recognizes the Fc region of antibody A and on the other side F (ab') 2 specifically recognizes the Fc region of antibody C;
wherein the bispecific antibody B is formed by coupling F (ab') 2 against the Fc-terminus of two antibodies of different species to each other.
6. The tetrameric antibody complex of claim 5,
the antibody A is a mouse anti-human CD3 antibody, a mouse anti-human CD4 antibody or a mouse anti-human CD8 antibody;
the antibody C is a rabbit anti-glucan antibody;
the bispecific antibody B was prepared from goat F (ab ') 2 anti-mouse IgG Fc and goat F (ab') 2 anti-rabbit IgG Fc.
7. The method for preparing the tetrameric antibody complex according to any one of claims 1 to 6, comprising the steps of obtaining a bispecific antibody B by a chemical coupling method, mixing the bispecific antibody B with an antibody A and an antibody C, and incubating the mixture to prepare the tetrameric antibody complex.
8. The method according to claim 7, wherein,
the molar ratio of the bispecific antibody B, antibody a and antibody C is 1:1:1, a step of;
the mixing time is 5-30 min.
9. A conjugate comprising the tetrameric antibody complex of any one of claims 1 to 6 and a solid support.
10. The conjugate of claim 9, wherein the solid support is dextran modified magnetic beads having a diameter of 50nm to 5 μm.
11. The use of the tetrameric antibody complex according to any one of claims 1 to 6 for cell separation and purification.
12. Use of the conjugate of claim 9 or 10 for cell separation and purification.
13. A reagent for separating and purifying cells, comprising the tetrameric antibody complex according to any one of claims 1 to 6.
14. A cell separation and purification reagent comprising the conjugate of claim 9 or 10.
15. A method for isolating and purifying cells, comprising isolating cells of interest from a sample using the reagent of claim 13 or 14.
16. The method of claim 15, wherein the sample comprises a tissue sample, whole blood, or PBMCs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410134120.4A CN117659204B (en) | 2024-01-31 | 2024-01-31 | Tetrameric antibody complex and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410134120.4A CN117659204B (en) | 2024-01-31 | 2024-01-31 | Tetrameric antibody complex and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117659204A true CN117659204A (en) | 2024-03-08 |
| CN117659204B CN117659204B (en) | 2024-06-11 |
Family
ID=90073481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410134120.4A Active CN117659204B (en) | 2024-01-31 | 2024-01-31 | Tetrameric antibody complex and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117659204B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4868109A (en) * | 1985-04-29 | 1989-09-19 | Lansdorp Peter M | Immunological antibody complex, its preparation and its use |
| CN105209608A (en) * | 2013-03-15 | 2015-12-30 | 干细胞技术公司 | Method for separating cells using immunorosettes and magnetic particles |
| CN107709366A (en) * | 2015-06-10 | 2018-02-16 | 干细胞技术公司 | The method being formed in situ for difunctional immune complex |
-
2024
- 2024-01-31 CN CN202410134120.4A patent/CN117659204B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4868109A (en) * | 1985-04-29 | 1989-09-19 | Lansdorp Peter M | Immunological antibody complex, its preparation and its use |
| CN105209608A (en) * | 2013-03-15 | 2015-12-30 | 干细胞技术公司 | Method for separating cells using immunorosettes and magnetic particles |
| CN107709366A (en) * | 2015-06-10 | 2018-02-16 | 干细胞技术公司 | The method being formed in situ for difunctional immune complex |
Non-Patent Citations (3)
| Title |
|---|
| HONGYAN LIU 等: ""Fc engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds"", 《FRONTIERS IN IMMUNOLOGY》, vol. 8, 26 January 2017 (2017-01-26), pages 1 - 15, XP093037588, DOI: 10.3389/fimmu.2017.00038 * |
| WEONU CHOE 等: ""Fc-Binding Ligands of Immunoglobulin G: An Overview of High Affinity Proteins and Peptides"", 《MATERIALS》, vol. 9, 8 December 2016 (2016-12-08), pages 1 - 17 * |
| 陈炯 等: ""hLCN6单克隆抗体偶联免疫磁珠用于混合细胞中精子的分离与法医学鉴定"", 《生物工程学报》, vol. 35, no. 1, 25 January 2019 (2019-01-25), pages 150 - 158 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117659204B (en) | 2024-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6987640B2 (en) | CD3 specific humanized antibody or fragment thereof | |
| JP3012326B2 (en) | Cleavage of antigen / anti-antigen | |
| CA2996848C (en) | Soluble antibody complexes for t cell or nk cell activation and expansion | |
| Lipman et al. | Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources | |
| JP4202251B2 (en) | Method for selecting antibody-expressing cells | |
| US20090306347A1 (en) | Antibody produced using ostrich and method for production thereof | |
| US20220056112A1 (en) | MONOCLONAL ANTIBODIES AGAINST SARS-CoV-2 NUCLEOCAPSID PROTEIN AND USES THEREOF | |
| WO2003000176A2 (en) | Conjugates of reduced antibodies and biomolecules | |
| CN117659204B (en) | Tetrameric antibody complex and application thereof | |
| CN110577598B (en) | anti-sFc epsilon RI alpha monoclonal antibody and application thereof | |
| CA2411392C (en) | Tetrameric antibody complexes for blocking non-specific binding of antigens | |
| US8470978B2 (en) | Method for separating viable cells, apoptotic and dead cells | |
| Bhatnagar et al. | Sequential affinity purification of peroxidase tagged bispecific anti-SARS-CoV antibodies on phenylboronic acid agarose | |
| EP2562185B1 (en) | Antibody against human TSH and canine TSH | |
| US9518131B2 (en) | Generating metal ion binding proteins | |
| JP2020536117A (en) | Antibodies and test devices for the detection of Campylobacter bacteria | |
| US20020155511A1 (en) | Novel antibody compositions for the negative selection of specific rat leukocyte subsets | |
| WO2023008404A1 (en) | Reagent containing humanized antibody | |
| EP4130032A1 (en) | Reagent containing antibody having partial deletion of fc region | |
| JPH05252986A (en) | Heterobifunctional antibody and its utilization | |
| CN112094345A (en) | Monoclonal antibody of mouse anti-immunoglobulin associated beta CD79b capable of being applied to tumor cell capture | |
| JP2023539279A (en) | Method for producing antibodies | |
| AU2012203085A1 (en) | Antibody produced using ostrich and method for production thereof | |
| JPH06504424A (en) | Monoclonal anti-IgM antibodies, their production and use, and hybridomas for producing them | |
| Bullido et al. | Monoclonal antibodies 2F6/8 and 2A10/8 recognize a porcine antigen (SWC7) expressed on B cells and activated T cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |